28 results on '"C Datz"'
Search Results
2. Variants in TM6SF2, PNPLA3 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis
3. Mortality is increased in NAFLD patients with homozygosity for PNPLA3 risk allele
4. Retreatment of patients with chronic hepatitis C who failed interferon-free direct acting antiviral therapy
5. Real world experience of retreatment of chronic hepatitis C patients who failed IFN-free DAA therapy
6. Variants in TM6SF2 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis
7. Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD
8. Influence of design and bearing material on polyethylene wear particle generation in total knee replacement
9. Sedation Training Using a Human Patient Simulator
10. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells
11. P0740 : Usefulness of interferon LAMBDA4-, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection
12. P0985 : Metabolomics profiling identifies potential pathways involved in the interaction of iron homeostasis with insulin resistance
13. 443 KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR 2DL3 AND ITS HLA-C LIGANDS DO NOT PREDICT SPONTANEOUS RESOLUTION IN PATIENTS WITH ACUTE HEPATITIS C
14. Immune response to natural and recombinant antigens of Helicobacter pylori in patients with dyspeptic complaints
15. 899 INFLUENCE OF GENDER, AGE AND ITPA POLYMORPHISM (rs6051702, rs1127354, rs7270101) ON THROMBOCYTOPENIA IN HCV GENOTYPE 1 AND 4 PATIENTS ON ANTIVIRAL THERAPY
16. Routine serum laboratory parameters for the staging of fibrosis in patients with chronic hepatitis C
17. 134 EVALUATION OF GENOME-WIDE LOCI OF IRON METABOLISM IN HEREDITARY HEMOCHROMATOSIS IDENTIFIES PCSK7 AS A PREDICTOR OF LIVER CIRRHOSIS
18. 1320 IL28B POLYMORPHISMS AND IP-10 ARE ASSOCIATED WITH ACUTE PRESENTATION AND SPONTANEOUS CLEARANCE IN RECENT HEPATITIS C VIRUS INFECTION
19. Induction treatment of chronic hepatitis C with daily interferon plus ribavirin plus amantadine is effective in non-responders to interferon plus ribavirin
20. 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’
21. O.161 High SVR rates with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 patients with a week-4 virological response
22. 567 A functional polymorphism in the glutathione-S-transferase P1 gene determines the progression to cirrhosis in patients with hereditary hemochromatosis
23. High dose interferon induction therapy does not improve response to combination therapy in relapsers and nonresponders to previous interferon monotherapy
24. Successful triple combination treatment of patients with chronic hepatitis C not responding to interferon plus ribavirin
25. Interferon (IFN) induction therapy in combination with ribavirin in chronic hepatitis C
26. Retreatment of ifn nonresponders (NR) or relapsers (REL) with chronic hepatitis c with high dose interferon (IFN) in combination with ribavirin
27. Effect of initial interferon dosing and dose on early response to combination therapy with ribavirin in chronic hepatitis C
28. HLA-H mutations in patients with chronic hepatitis C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.